Arcellx and kite continue momentum with advances in anito-cel multiple myeloma program

Redwood city, calif. & santa monica, calif.--(business wire)--arcellx, inc. (nasdaq: aclx) and kite, a gilead company (nasdaq: gild), today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. anito-cel is the first bcma car t to be investigated in multiple myeloma that utilizes arcellx's novel and compact d-domain binder. the companies shared the design of a global, phase 3 randomized controlled clinical trial, immagine-3,.
ACLX Ratings Summary
ACLX Quant Ranking